FY2014 Goals – Results 20 Build shareholder value through: Continued leadership in epilepsy medical devices Consistent sales & profitability growth worldwide Achieving clinical & product development milestones EU regulatory approval of the AspireSR ® generator Enrollment completed for AspireSR ® E-37 clinical study Evaluating & advancing other neuroscience opportunities Apnex asset purchase (obstructive sleep apnea) Increased investments in Imthera ™ & cerbomed 
{}